Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varegacestat Bioavailability and Bioequivalence Study in Healthy Participants
NCT07610005Phase 1Recruiting
- Sponsor
- Immunome
- Start
- May 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varegacestat (6 arms), sponsored by Immunome. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at 3 weeks, Area Under the Curve from Time Zero to Infinity at 3 weeks and 1 more. Started May 2026; status: recruiting.
02
Drugs
varegacestat
Beyond the preview
Go deeper on NCT07610005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610005.